Analyst Tiago Fauth of Wells Fargo reiterated a Buy rating on Tectonic Therapeutic (TECX – Research Report), reducing the price target to $101.00.
Tiago Fauth has given his Buy rating due to a combination of factors that highlight the potential of Tectonic Therapeutic’s stock. The company is perceived as undervalued, especially in light of a competitor’s program discontinuation and misunderstandings regarding the relaxin mechanism. These factors create a compelling risk/reward scenario for investors.
Furthermore, Tectonic’s upcoming catalysts in the second half of 2025 and 2026 are on track, with promising data expected from TX45’s trials. The company’s financial position is strong, with sufficient cash reserves to support operations and key developments through mid-2027. Despite skepticism around the efficacy of relaxin in Group 2 PH, TX45 has demonstrated significant efficacy, distinguishing it from other treatments. This positions Tectonic Therapeutic favorably in the market.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TECX in relation to earlier this year.